Category: elsevier

Elsevier retracts entire issue after mistakenly publishing it online

Publishing giant Elsevier has retracted an entire issue of one of its journals because the contents — abstracts from a conference about child neurology — were never supposed to make it online.

We discovered the retraction after realizing that every aspect of the issue in Brain & Development had been retracted, including the cover, editorial board, and the contents.

We contacted Elsevier, and a spokesperson told us:

Continue reading Elsevier retracts entire issue after mistakenly publishing it online

Fearing “stigmatization,” patient’s father seeks retraction of paper on rare genetic mutation

The father of a boy with a rare genetic mutation has accused a scientist of exploiting his child by proclaiming the defect a “genetic syndrome” and naming it after herself.

At an impasse with scientists investigating, publicizing, and interpreting his son’s condition, the father seems willing to use any leverage he can muster to remove the “syndrome” entry in an online genetic disease database. Based solely on an email he obtained from the database director, the father became convinced that if the paper underpinning the entry were retracted, the syndrome would go down with it. So earlier this year, he withdrew his consent and asked the journal that published the paper for a retraction, based on improper patient consent. He has also threatened to lob accusations of research misconduct at the paper’s last author. Continue reading Fearing “stigmatization,” patient’s father seeks retraction of paper on rare genetic mutation

The three-year delay: Journal finally retracts paper based on made-up data

Three years after an investigation revealed a 2013 paper was based on fraudulent data, a journal has finally retracted it.

The paper, published in Journal of Hazardous Materials, was one of seven articles by a team at the Institute of Microbial Technology (IMTECH) in Chandigarh, India that contain fabricated data, according to an investigation by the Council of Scientific and Industrial Research in New Delhi. (IMTECH is part of the Council of Scientific and Industrial Research.) Although it took one journal years to take action, another still has not retracted one of the seven flagged papers. Continue reading The three-year delay: Journal finally retracts paper based on made-up data

After investigation that started at least 5 years ago, retired ob-gyn prof agrees to 5 years of supervision

Nasser Chegini

A now-retired professor tweaked the findings in seven figures of a 2007 paper, according to a new finding of misconduct released yesterday by the U.S. Office of Research Integrity.

The subject of the findings isn’t a stranger to our readers: We’ve already reported on nine retractions for Nasser Chegini, a former professor of obstetrics and gynecology at the University of Florida (UF) who had won more than $4 million in Federal grants. And Chegini, who retired in early 2012, had been under investigation since at least 2012, with the ORI asking UF to broaden that investigation at one point.

Indeed, the ORI’s notice states that eight of Chegini’s retractions resulted from the UF’s investigation. The ORI’s findings, however, stem from another paper, published in the Journal of Reproductive Immunology, which has not been retracted.

According to the ORI, in that paper, Chegini:

Continue reading After investigation that started at least 5 years ago, retired ob-gyn prof agrees to 5 years of supervision

Why did it take a journal two years to retract a paper after a misconduct finding?

A 2014 paper containing data manipulated by a former graduate student has finally been retracted, two years after the U.S. Office of Research Integrity (ORI) published its findings.

In August 2015, the ORI published a report that Peter Littlefield, who was working on his PhD at the University of California, San Francisco (UCSF), had committed “research misconduct by falsifying and/or fabricating data” in two papers. Littlefield agreed to correct or retract the papers–one published in Chemistry & Biology and the other in Science Signaling.  

When we contacted Chemistry & Biology back in August 2015, a spokesperson for Cell Press told us the journal was figuring out “the best way to correct the scientific record.”

Apparently that took two years. In the meantime, the journal did not issue an expression of concern or otherwise notify readers of the issues. Continue reading Why did it take a journal two years to retract a paper after a misconduct finding?

Work by group at Australian university faces scrutiny

A journal is investigating research by a group in Australia, after receiving “serious allegations” regarding a 2017 paper about treating eye burns.

The journal, Frontiers in Pharmacology, has issued an expression of concern (EOC) for the 2017 paper while it investigates. The notice does not specify the nature of the allegations.  Meanwhile, several other papers by the three researchers, based at Deakin University in Geelong, Australia, have also come under scrutiny. Late last month, Frontiers in Pharmacology retracted a 2015 paper by Kislay Roy, Rupinder Kanwar, and Jagat R Kanwar, citing image duplication. A 2015 paper in Biomaterials received a correction in May 2017, again flagging image duplication.

Roy, the first author on the papers, is a postdoctoral research fellow; Rupinder Kanwar, a middle author, is a senior lecturer; and Jagat R Kanwar, the corresponding author on all three, is head of the Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research.

Gearóid Ó Faoleán, the ethics and integrity manager at Frontiers in Pharmacology, explained that the investigation into the flagged article is ongoing and the EOC “must serve as the extent of our public statement for the present.”

A spokesperson for Deakin University declined to comment on the allegations: Continue reading Work by group at Australian university faces scrutiny

“We do not want to create false hope”: Authors retract Cell paper they can’t replicate

A few years ago, researchers in Sweden had something to celebrate: They thought they had discovered a chink in the armor of the most common type of malignant brain cancer.

In a 2014 Cell paper, the team — led by Patrik Ernfors at the Karolinska Institutet — reported that they had identified a small molecule that could target and kill glioblastoma cells — the cancer that U.S. Senator John McCain was just diagnosed with — and prolong survival in mice with the disease. 

Satish Srinivas Kitambi, the paper’s first author, who is also based at the Karolinska Institutet, said the results got the team “really excited:” Continue reading “We do not want to create false hope”: Authors retract Cell paper they can’t replicate

NIH neuroscientist up to 19 retractions

Stanley Rapoport.
Source: NIH

The string of apparent bad luck continues for Stanley Rapoport.

Rapoport, a neuroscientist based at the U.S. National Institute on Aging, has lost three more papers in three journals due to the misconduct of his co-authors. By our count, these retractions bring his tally to 19 — and tie him for 21st place on our leaderboard.

The journals—Schizophrenia Research, Journal of Affective Disorders, and Biological Psychiatry— retracted the papers because the National Institutes of Health had found that one of Rapoport’s co-authors, Jagadeesh Rao, had “engaged in research misconduct by falsifying data.” Rao was corresponding author on all three papers.

According to a spokesperson for Elsevier, which publishes the journals, the Schizophrenia Research paper was retracted in July, the JAD paper in late May and the Biological Psychiatry paper in late April. The spokesperson told us that the publisher first received an email from the NIH about the misconduct findings on September 20, 2016, and that: Continue reading NIH neuroscientist up to 19 retractions

Want to appeal a journal’s rejection? Sure — that’ll be $700

Different journals follow different editorial policies — but we’ve never seen any charge money to authors who want to appeal an editorial decision. Until now.

Recently, a criminal justice researcher sent us links to multiple journals that charge appeal fees. For instance, the Journal of Accounting Research says authors must pay $500 for each submission — and another $500 if they want the journal to reconsider its decision to reject the paper.

Under “Appeals,” the journal writes:

Continue reading Want to appeal a journal’s rejection? Sure — that’ll be $700

Lancet retracts (and replaces) paper a year after authors report error that changes “all numbers”

In March 2016, researchers in Switzerland and Canada published a meta-analysis in The Lancet, exploring the optimal painkiller and dose for treating pain in knee and hip osteoarthritis. Soon after, the authors were informed of an error that would change “all numbers” in a paper that may influence clinical practice.

The authors contacted The Lancet immediately, in July 2016, to inform them of the issue. Sven Trelle, the paper’s corresponding author, also told us: Continue reading Lancet retracts (and replaces) paper a year after authors report error that changes “all numbers”